达尔西利在乳腺癌治疗中的研究进展
Research progress of dalpiciclib in treatment of breast cancer
都彩莹 1全香花 2孙彩红 1元海丹1
作者信息
- 1. 延边大学药学院,延吉 133002,吉林
- 2. 青岛大学附属医院药学部,青岛 266003,山东
- 折叠
摘要
达尔西利是首个国产原研的细胞周期蛋白依赖性激酶4/6抑制剂,国家药品监督管理局已批准其联合氟维司群或芳香化酶抑制剂治疗激素受体阳性/人表皮生长因子受体2阴性的晚期或转移性乳腺癌.本文主要介绍了达尔西利在乳腺癌中的研究进展,总结药物的作用机制、Ⅰ-Ⅲ期临床试验、以及药物安全性等问题.
Abstract
As the first domestically originated cell cycle protein-dependent kinase 4/6 inhibitor,dalpiciclib has been approved by the State Drug Ad-ministration for the treatment of hormone recep-tor-positive/human epidermal growth factor recep-tor 2-negative advanced or metastatic breast can-cer in combination with fulvestrant or aromatase inhibitors.This article focuses on the progress of dalpiciclib research in breast cancer,summarizing the drug's mechanism of action,phase Ⅰ-Ⅲ clinical trials,and drug safety issues.
关键词
达尔西利/细胞周期蛋白依赖性激酶4/6/乳腺癌/临床试验Key words
dalpiciclib/cyclin-dependent kinase 4/6/breast cancer/clinical trials引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据